Start your patients on Otezla
DISCOVER RESULTS IN
Plaque Psoriasis^*†

*†The efficacy and safety of Otezla was evaluated in 2 multicenter, double-blind, placebo-controlled trials of similar design. Patients with moderate to severe plaque psoriasis (N = 1257) were randomized 2:1 to Otezla 30 mg twice daily or placebo for 16 weeks after a 5-day titration.^1,3,4 In ESTEEM 1, Otezla significantly increased PASI-75 response (n = 562) at week 16 (primary endpoint) vs placebo (n = 282) (33% vs 5%; P < 0.0001).^1,3

The most common adverse reactions (≥5%) were diarrhea, nausea, upper respiratory tract infection, tension headache, and headache.¹